Advertisement

Gastric Cancer

, Volume 22, Issue 4, pp 803–816 | Cite as

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

  • Manish A. ShahEmail author
  • Yoon-Koo Kang
  • Peter C. Thuss-Patience
  • Atsushi Ohtsu
  • Jaffer A. Ajani
  • Eric Van Cutsem
  • Silke Hoersch
  • Marie-Laurence Harle-Yge
  • Sanne Lysbet de Haas
Original Article
  • 382 Downloads

Abstract

Background

Prespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival benefit from trastuzumab emtansine (T-DM1) versus taxane therapy, and to advance understanding of HER2-positive advanced gastric/gastroesophageal junction cancer (AGC) disease biology.

Methods

Adults with HER2-positive AGC whose disease progressed during/after first-line therapy were enrolled and randomized to receive T-DM1 [Stage 1: 3.6 mg/kg q3w, 2.4 mg/kg qw, or taxane (docetaxel/paclitaxel); Stage 2: 2.4 mg/kg qw or taxane]. Primary efficacy endpoint was overall survival (OS). Prespecified exploratory biomarkers included HER2, HER3, PTEN, PIK3CA mutation status, FcγR, and cMET. Tumor samples from patients who received 2.4 mg/kg T-DM1 (n = 228) or taxane (n = 117) were included.

Results

Median OS was longer in subgroups with HER2 immunohistochemistry (IHC) 3+ [9.5 versus 8.3 months for T-DM1 versus taxane; hazard ratio (HR) 0.99 (95% CI 0.68–1.43)] versus HER2 IHC 2+/in situ hybridization-positive [5.2 versus 9.2 months for T-DM1 versus taxane; HR 1.53 (95% CI 0.94–2.50)] tumors. Trends towards increased median OS were also observed in subgroups with > versus ≤ median HER2 mRNA expression, higher versus lower HER2 gene copy number, HER2 gene ratio and H score, and homogenous or nonfocal HER2 IHC staining. T-DM1 was not associated with superior OS versus taxane in any subgroup.

Conclusions

Patients with previously treated HER2-positive AGC with higher HER2 expression experienced a better treatment effect from T-DM1 than those with lower HER2 expression and may derive comparable survival benefits from T-DM1 and taxane therapy.

Clinical trials registration

NCT01641939 (https://clinicaltrials.gov/ct2/show/NCT01641939).

Keywords

Trastuzumab emtansine Gastric cancer Gastroesophageal junction Biomarkers 

Notes

Acknowledgements

We would like to acknowledge all patients and investigators participating in this trial and the central testing and biomarker laboratories (Targos Molecular Pathology GmbH, Kassel, Germany; Aros Applied Biotechnology A/S, Aarhus, Denmark; Genentech, Inc., BRM Operations Handling, South San Francisco, CA). We also gratefully acknowledge the contributions of Tina van Der Horst to all data analyses, and of Dr. Marjorie Green to the design and conduct of the study. Support for third-party writing assistance for this manuscript, furnished by Debbie Briggs, Ph.D., and Rachel Johnson, Ph.D., of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Author contributions

Conception and design: MAS, PCT-P, SLH, JAA, M-LH-Y. Acquisition of data: MAS, Y-KK, PCT-P, EC, SLH, M-LH-Y. Analysis and interpretation of data: MAS, Y-KK, PCT-P, AO, EC, SLH, SH, M-LH-Y. Writing, review, and/or revision of the manuscript: MAS, Y-KK, PCT-P, AO, JAA, EC, M-LH-Y, SLH, SH. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Study supervision: MAS.

Funding

The sponsor of the GATSBY study was F. Hoffmann-La Roche Ltd, Basel, Switzerland. F. Hoffmann-La Roche Ltd was involved in the study design, the data interpretation, and the decision to submit for publication in conjunction with the authors.

Compliance with ethical standards

Disclosure of prior publication/presentation

This exploratory biomarker analysis has not been presented previously. Selected baseline data and univariate analyses have been published in the primary analysis: Thuss-Patience et al. [13].

Conflict of interest

Manish A. Shah has received research funding from Roche, Boston Biomedical, and Merck. Yoon-Koo Kang has acted in a consulting or advisory role for Novartis, Roche, BMS, Ono, Daehwa, and Blueprint and has received research funding from Daehwa. Peter C. Thuss-Patience has acted in a consulting or advisory role for Roche, Lilly, Pfizer, MSD, BMS, and Nordic and has received research funding (institutional support) from GSK and Novartis, and travel, accommodation, and expenses from Roche, Merck-KGaA, and TEVA. Atsushi Ohtsu has received research funding from BMS and a family member is employed by Celgene. Jaffer A. Ajani has received honoraria from BMS, Merck, Lilly, Taiho, and Astellas, has acted in a consulting or advisory role for Lilly, BMS, Insys, and AstraZeneca Medpace, and has received research funding from Merck, Delta-Fly, Gilead, Roche, and BMS. Eric Van Cutsem has acted in a consulting or advisory role for Bayer, Lilly, Roche, and Servier, and has received research funding (institutional support) from Amgen, Bayer, Boehringer, Lilly, Novartis, Roche, Sanofi, Celgene, Servier, Merck-KGaA, Merck, and Ipsen. Silke Hoersch is employed by KOEHLER eClinical and F. Hoffmann-La Roche. Marie-Laurence Harle-Yge is employed by F. Hoffmann-La Roche. Sanne Lysbet de Haas is employed by F. Hoffmann-La Roche.

Human rights statement

GATSBY was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol was approved at each site by the local ethics committee/institutional review board. All patients provided written informed consent.

Supplementary material

10120_2018_923_MOESM1_ESM.docx (213 kb)
Supplementary material 1 (DOCX 213 KB)

References

  1. 1.
    Roche Registration Ltd. Herceptin® (trastuzumab). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf. Accessed Sept 2018.
  2. 2.
    Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi57–63.Google Scholar
  3. 3.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer. Version 3. 2016. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed Aug 2016.
  4. 4.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  5. 5.
    Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget. 2015;6:5072–87.Google Scholar
  6. 6.
    Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.CrossRefGoogle Scholar
  7. 7.
    Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347–56.CrossRefGoogle Scholar
  8. 8.
    Krop IE, Kim S, González-Martín A, LoRusso PM, Ferrero J, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–99.CrossRefGoogle Scholar
  9. 9.
    Wildiers H, Kim S, Gonzalez-Martin A, LoRusso PM, Ferrero J, Yu R, et al. Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: final overall survival results from the phase 3 TH3RESA study. Cancer Res. 2016;76:Abstract S5-05 (and associated oral presentation).CrossRefGoogle Scholar
  10. 10.
    Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.CrossRefGoogle Scholar
  11. 11.
    Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res. 2016;22:3755–63.CrossRefGoogle Scholar
  12. 12.
    Kim S, Wildiers H, Krop IE, Leung ACF, Trudeau C, Yu R, et al. Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib. J Clin Oncol. 2014;32(20 May suppl.):Abstract 605.CrossRefGoogle Scholar
  13. 13.
    Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53.CrossRefGoogle Scholar
  14. 14.
    Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003;100:8933–8.CrossRefGoogle Scholar
  15. 15.
    Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.CrossRefGoogle Scholar
  16. 16.
    Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240–5.CrossRefGoogle Scholar
  17. 17.
    Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:10992–1000.CrossRefGoogle Scholar
  18. 18.
    Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–27.CrossRefGoogle Scholar
  19. 19.
    Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68:9221–30.CrossRefGoogle Scholar
  20. 20.
    Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.CrossRefGoogle Scholar
  21. 21.
    Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008;68:1471–7.CrossRefGoogle Scholar
  22. 22.
    Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 2012;11:660–9.CrossRefGoogle Scholar
  23. 23.
    Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753–61.CrossRefGoogle Scholar
  24. 24.
    Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32:3212–20.CrossRefGoogle Scholar
  25. 25.
    Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32:1437–44.CrossRefGoogle Scholar
  26. 26.
    McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s-8s.Google Scholar
  27. 27.
    Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction. Oncologist. 2016;21:1085–90.CrossRefGoogle Scholar
  28. 28.
    Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics. 2004;5:465–81.CrossRefGoogle Scholar
  29. 29.
    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRefGoogle Scholar
  30. 30.
    Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver MJ, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.CrossRefGoogle Scholar
  31. 31.
    Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–50.CrossRefGoogle Scholar
  32. 32.
    Van Cutsem E, Bang Y, Feng-yi F, Xu JM, Lee K, Jiao S, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476–84.CrossRefGoogle Scholar
  33. 33.
    Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.CrossRefGoogle Scholar
  34. 34.
    Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, et al. HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib. Mol Cancer Ther. 2017;16:228–38.CrossRefGoogle Scholar
  35. 35.
    Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol. 2014;32:2039–49.CrossRefGoogle Scholar
  36. 36.
    Peng Z, Zou J, Zhang X, Yang Y, Gao J, Li Y, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chin J Cancer Res. 2015;27:163–71.Google Scholar
  37. 37.
    Seo S, Ryu MH, Ahn JY, Park Y, Park SR, Ryoo BY, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of GASTric cancer HER2 reassessment study 3 (GASTHER3). J Clin Oncol. 2017;35(4 Suppl):Abstract 27.CrossRefGoogle Scholar
  38. 38.
    Esaki T, Makiyama A, Kashiwada T, Hosokawa A, Kawada J, Moriwaki T, et al. T-ACT (WJOG7112G): a randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. J Clin Oncol. 2017;35(4 Suppl):TPS218.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  • Manish A. Shah
    • 1
    • 10
    Email author
  • Yoon-Koo Kang
    • 2
  • Peter C. Thuss-Patience
    • 3
  • Atsushi Ohtsu
    • 4
  • Jaffer A. Ajani
    • 5
  • Eric Van Cutsem
    • 6
  • Silke Hoersch
    • 7
  • Marie-Laurence Harle-Yge
    • 8
  • Sanne Lysbet de Haas
    • 9
  1. 1.Division of Hematology and Medical OncologyMeyer Cancer Center of Weill Cornell Medical CollegeNew YorkUSA
  2. 2.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  3. 3.Department of Hematology, Oncology and Tumor ImmunologyCharité – University Medicine BerlinBerlinGermany
  4. 4.Department of GI Oncology/GastroenterologyNational Cancer Center Hospital EastKashiwaJapan
  5. 5.Department of Gastrointestinal Medical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Digestive OncologyUniversity Hospitals Gasthuisberg Leuven and KU LeuvenLeuvenBelgium
  7. 7.Statistics DepartmentKOEHLER eClinical GmbHFreiburgGermany
  8. 8.Pharmaceutical Development Clinical OncologyF. Hoffmann-La Roche LtdBaselSwitzerland
  9. 9.Department of Oncology Biomarker DevelopmentF. Hoffmann-La Roche LtdBaselSwitzerland
  10. 10.Solid Tumor Service, Gastrointestinal OncologyWeill Cornell Medicine/New York-Presbyterian HospitalNew YorkUSA

Personalised recommendations